NORD Advocacy Agenda Includes End To Lifetime Caps, Reimbursement Of Some Off-Label Uses
This article was originally published in The Pink Sheet Daily
Executive Summary
Time is short for rare disease advocates to get their provisions included in federal health care reform legislation, group is warned.
You may also be interested in...
Health Reform And Rare Diseases: Orphan Drugs May Do Well Amid Changes
Advocates for patients with rare diseases are urging Congress to build in special considerations for treatments for rare diseases in several key provisions of health care reform
Orphans Wanted: FDA Offers New Ideas For Rare Disease Drug Development
FDA's top review managers have a message for drug developers: they are eager to find creative ways to work with sponsors to bring new treatments for rare diseases to market
Health Reform And Rare Diseases: Orphan Drugs May Do Well Amid Changes
Advocates for patients with rare diseases are urging Congress to build in special considerations for treatments for rare diseases in several key provisions of health care reform